Foodresearchlab123
Uploaded on Feb 18, 2026
Category
Health & Medicine
Explore the FDA's recommendation to classify synthetic 7-Hydroxymitragynine (7-OH) as a Schedule I substance, its public health implications, and nutraceutical product innovation focused on safety in kratom-derived formulations
Category
Health & Medicine
FDA Recommends Scheduling of Synthetic 7-Hydroxymitragynine (7-OH) from Kratom
FDA RECOMMENDS SCHEDULING
SYNTHETIC 7-HYDROXYMITRaGYNINE
(7-OH) Food Research
Lab
Overview
Kratom contains natural alkaloids; 7-OH
is one of its potent compounds.
7-OH shows opioid-like effects at
higher concentrations.
FDA UPDaTE
FDA (July 29, 2025) recommends DEA to
place synthetic/concentrated 7-OH
under Schedule I.
Natural kratom leaf is not included.
SaFETY CONCERNS
7-OH is 10–13x more potent than
morphine.
Risks: respiratory depression,
addiction, seizures, withdrawal.
No FDA-approved uses.
MaRKET & REGULaTORY
RISK7S-OH products sold as
supplements/foods are considered
adulterated.
FDA has issued warning letters to
brands selling gummies, shots, drink
mixes.
Youth-appealing products raise
additional concerns.
CONTACT
+91 95662 99022
info@foodresearchlab.
com
www.foodresearchlab.c
om
Comments